 
 Protocol with Statistical Analysis Plan Cover Page:   
 
Official Title:  Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune 
Activation in Psoriasis 
NCT number:  [STUDY_ID_REMOVED] 
Document Type:   Protocol with Statistical Analysis Plan (SAP)  
Document Date:  July 21, 2023 
  
1 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
Abbreviated Title: NR in psoriasis 
Protocol: 20H0044 ( P194768)  
Version Date: July 21, 2023 
 
Title: Pilot Study to Evaluate the Ef fect of Nicotinami de Riboside on Immune Activation in 
Psoriasis 
 
 
NIH Principal Investigator: Michael N. Sack, MD, Ph.D. 
Cardiovascular Branch, NHLBI 
Building 10-CRC, Rm 5-3342 10 Center lane, Bethesda, MD 20892 Phone: 301-402-9259 E-mail: sackm@nih.gov 
2 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
TABLE OF CONTENTS 
Contents 
TABLE OF CONTENTS ............................................................................................................. .................. 2  
STATEMENT OF COMPLIANCE ....................................................................................................... ........ 5  
1 PROTOCOL SUMMARY .............................................................................................................. ....... 6  
2 INTRODUCTION .................................................................................................................. ............. 11  
2.3.1  Known Potential Risks ......................................................................................................... ......... 14  
Known Potential Benefits ...................................................................................................... ...................... 15  
2.3.2  Assessment of Potential Risks and Benefits .................................................................................. 1 5 
3 OBJECTIVES AND ENDPOINTS ..................................................................................................... 15 
5. STUDY POPULATION .............................................................................................................. ........ 17  
Rationale for the exclusio n of pregnant women ................................................................................. ......... 18  
Rationale for the exclusion of cognitively impaired subjects .................................................................. .... 18  
5.6.1  Costs ......................................................................................................................... ..................... 19  
5.6.2  Compensation .................................................................................................................. .............. 19  
6 STUDY INTERVENTION ............................................................................................................ ...... 19  
6.1.1  Study Intervention Description ................................................................................................ ...... 19  
6.1.2  Dosing and Administration ..................................................................................................... ...... 20  
6.1.3  Dose Escalation ............................................................................................................... .............. 20  
6.1.4  Dose Limiting Toxicity ........................................................................................................ ......... 20  
6.1.5  Dose Modifications ............................................................................................................ ........... 20  
6.1.6  Drug Adminis tratio n ........................................................................................................... ........... 20  
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY .................................................... 20  
6.2.1  Acquisition and Accountability ................................................................................................ ..... 20  
6.2.2  Formulation, Appearance, Packaging, and Labeling .................................................................... 20  
6.2.3  Product Storage and Stability ................................................................................................. ....... 21  
6.2.4  Preparation ................................................................................................................... ................. 21  
6.3 MEASURES TO MINIMIZE BIAS: R ANDOMIZATION AND BLINDING .................................. 21  
6.4 STUDY INTERVENTION COMPLIANCE ....................................................................................... 21  
6.5 CONCOMITANT THERAPY ........................................................................................................... .. 21 
7 STUDY INTERVENTION DISCONTI NUATION AND PARTICIPANT 
3 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 DISCONTINUATION/WITHDRAWAL ............................................................................................ 21  
7.1 Discontinuation Of Study Intervention ......................................................................................... ....... 21  
7.3 LOST TO FOLLOW-UP ............................................................................................................. ........ 22  
8 STUDY ASSESSMENTS AND  PROCEDURES ............................................................................... 22  
8.2.1  Clinical Evaluations .......................................................................................................... ............ 23  
8.2.2  Biospecimen Evaluations ....................................................................................................... ....... 23  
8.2.3  Correlative Studies for Research /Pharmacokinetic Studies .......................................................... 24  
8.2.4  Samples for Genetic/Genomic Analysis ........................................................................................ 2 4 
8.4.1  Definition of Adverse Event ................................................................................................... ....... 24  
8.4.2  Definition of Serious Ad verse Events (SAE) ................................................................................ 24  
8.4.3  Classification of an Adverse Event............................................................................................. ... 25  
8.4.3.2  Relationship to Study Intervention......................................................................................... 25  
8.4.3.3  Expectedness .................................................................................................................. ........ 26  
8.4.4  Time Period and Frequency for Ev ent Assessment and Follow-Up ............................................. 26  
8.4.5  Adverse Event Reporting........................................................................................................ ....... 27  
8.4.6  Serious Adverse Event Reporting ............................................................................................... ... 27  
8.4.7  Events of Special Interest .................................................................................................... .......... 27  
8.4.8  Reporting of Pregnancy ........................................................................................................ ......... 28  
8.5.1  Definition of Unanticipated Problems (UP) .................................................................................. 28  
8.5.2  Unanticipated Problem Reporting ............................................................................................... .. 28 
8.5.3  NIH Intramural IRB Reporting of IND Safety Reports ................................................................. 29  
9 STATISTICAL CONSIDERATIONS ................................................................................................. 29  
9.3 POPULATIONS FO R ANALYSES .................................................................................................... 3 0 
9.3.1  Evaluable for toxicity ........................................................................................................ ............ 30  
9.3.2  Evaluable for objective response .............................................................................................. ..... 30  
9.4 STATISTICAL ANALYSES .......................................................................................................... ..... 30  
9.4.1  General Approach .............................................................................................................. ............ 30  
9.4.2  Analysis of the Primary Endpoints ............................................................................................. ... 30  
9.4.3  Analysis of the Secondary Endpoint(s) .........................................................................................  30 
9.4.4  Safety Analyses ............................................................................................................... .............. 30  
9.4.5  Baseline Descriptive Statistics ............................................................................................... ....... 30  
10 REGULATORY AND OPERATIO NAL CONSIDERATIONS ......................................................... 30  
4 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 10.1  INFORMED CONSENT PROCESS ................................................................................................... 30  
10.1.1  Consent/Assent Procedures  and Documentation ........................................................................... 30  
10.1.2  Consent for minors when they r each the age of majority .............................................................. 31  
10.1.3  Telephone consent ............................................................................................................. ............ 31  
10.1.4  Participation of Subjects who are/beco me Decisionally Impaired N/A ......................................... 31  
10.1  STUDY DISCONTINUATIO N AND CLOSURE .............................................................................. 32  
10.2  CONFIDENTIALITY AND PRIVACY .............................................................................................. 32  
10.3  FUTURE USE OF STORED SPECIMENS AND DATA .................................................................. 33  
10.4  SAFETY OVERSIGHT .............................................................................................................. ......... 33  
10.5  CLINICAL MONITORING ........................................................................................................... ..... 33  
10.6  QUALITY ASSURANCE AND QUALITY CONTROL ................................................................... 33  
10.7  DATA HANDLING AND RECORD KEEPING ................................................................................ 34  
10.8.1  Data Collection and Management Responsibilities ....................................................................... 34  
10.8.2  Study Records Retention ....................................................................................................... ........ 34  
10.8  PROTOCOL DEVIATIONS ........................................................................................................... .... 34  
10.9  PUBLICATION AND DATA SHARING POLICY ........................................................................... 35  
10.10.1  Human Data Sharing Plan ...................................................................................................... 35 
10.10.2  Genomic Data Sharing Plan ................................................................................................... 3 5 
10.10  COLLABORATIONS AND AGREEMENTS ............................................................................. 35  
10.11.1 Agreement Type ........................................................................................................ ...................... 35  
10.11  CONFLICT OF INTEREST POLICY .......................................................................................... 35  
11 ABBREVIATIONS ................................................................................................................. ............ 36  
12 REFERENCES .................................................................................................................... ................ 37  
 
5 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 STATEMENT OF COMPLIANCE 
The trial will be carried out in accordance w ith International Confer ence on Harmonisation Good 
Clinical Practice (ICH GC P) and the following: 
x United States (US) Code of Federal Regulations  (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CF R Part 56, and 21 CFR Part 312) 
National Institutes of Health (NIH)-funded invest igators and clinical tr ial site staff who are 
responsible for the conduct, ma nagement, or oversight of NIH -funded clinical trials have 
completed Human Subjects Prot ection and ICH GCP Training. 
The protocol, informed consent form(s), recruitmen t materials, and all part icipant materials will be 
submitted to the Institutional Review Board (IRB)  for review and approva l. Approval of both the 
protocol and the consent form must be obtained before any participant is enrolled. Any 
amendment to the protocol will require review and approval by the IRB before the changes are 
implemented to the study. In addi tion, all changes to the consent form will be IRB-approved; a 
determination will be made regarding whethe r a new consent needs to be obtained from 
participants who provided consent, usi ng a previously approved consent form 
6 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
1 PROTOCOL SUMMARY 
1.1 SYNOPSIS 
Title: Pilot Study to Evaluate the Eff ect of Nicotinamide Riboside on 
Immune Activation in Psoriasis 
Study Description:          Psoriasis is a Th17 linked inflammato ry disease and we find that the 
vitamin B3 analogue nicotinamide ri boside (NR) blunts Th1 and Th17 
activation in ex-vivo naÃ¯ve and differentiated T cells from control and psoriasis subjects. These findings  supported the proposal of the 
following hypothesis. Supplementation with NR will blunt systemic immune activation in mild/moderate psoriasis. 
Objectives: 1) Evaluate the effect of NR on Th17 biology 
2) Explore the effect of NR on ne utrophils, specifically low- 
density granulocytes 
3) Evaluate whether NR modulates keratinocyte activation in skin 
lesions in psoriatic subjects 
4) Evaluate the effect of NR on HDL regulated reverse 
cholesterol transport and lipid composition 
 
Endpoints: The primary outcome will be  the change in the T H17 cell cytokine IL- 
17 secretion in response to T- cell differentiation comparing the 
baseline versus NR or placebo. The comparisons will be performed using paired two-tailed Student t-tests. Significance will be tested at 
the 0.05 alpha level in this pilot study. 
Exploratory outcomes are: 
1) Evaluate the effect of NR on the T cell transcriptome 
2) Explore the effect of NR on low-density granulocytes and 
neutrophils 
Study Population: Up to 40 male and female subjects of all races between the ages of 
18-80 years with mild-moderate psor iasis who live locally will be 
screened . 
Phase: N/A 
Description of Sites/Facilities Enrolling Participants: Enrollment and study visits will take place at the NIH Clinical Center 
or via telehealth visits . 
Psoriatic Subjects 
7 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 Description of Study 
Intervention: Nicotinamide Riboside Chloride 50 0mg or placebo twice daily by 
mouth for 28 days. 
 
Study Duration:              3 years 
Participant Duration: 5-23 weeks 
8
Abbreviated Title: NR in psoriasis
Version Date: 07/21/2023
Template version date 07-29-20191.2 S CHEMA
Day -120 to Day -1 Screening Nicotinamide Riboside
N=18
Day 0 Randomization
(Baseline)
Day 28 Visit 2 
Day 29 to 35 Safety Visit (if
applicable)# in-clinic
or 
telehealth
visit =2
Placebo N=9
9 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
1.3 SCHEDULE OF ACTIVITIES (SOA) 
 
 
EVALUATION AND ASSESSMENTS   
Screening 
(A)   
Baseline 
Visit*  
28 day 
Visit *  
Safety visit (if 
applicable) 
PROTOCOL TIMEPOINT VISITS    1 2 3 
    D0 D28  
 
Window +/- days  -120Days   +/- 7 D  
Assessments & Consents       
Review Inclusion/Exclusion Criteria  x     
Medical History  x     
Physical Examination  X3  X3 X3 X3 
Medication Review  x  x x  
Vital Signs    X3 X3 X3 
Consent to Study  x  x   
Adverse Event Review     x x 
CHEMISTRY LABS       
Female, Pregnancy Test (blood or urine)  x1  x1 x1  
Acute Care Panel  x  x x x 
Mineral Panel    x x x 
Hepatic Panel  x  x x x 
hs-CRP    x x x 
Uric Acid  x     
Fasting Lipid Panel    x x  
HEMATOLOGY LABS       
CBC with differential  x  x x x 
Research Samples       
PBMCâ€™s    x x  
Serum    x x  
Procedures       
Skin Punch Biopsy (lesion and non-lesion)    X3 X3  
PASI (Psoriasis Area and Severity Index)  x     
Study Medication       
Dispense study pills    x   
Compliance (pill count)     x2  
Return of study pills     x  
       
A. Labs and assessments may be used for baseline visit if performed within 14 days 
B. Unscheduled safety visit for those patients with clinically significant ongoing adverse events from month 1 visit 
or reported to site within 7 days from last dose of stud y drug. All procedures or testing noted above are optional. 
x1 = Pregnancy testing for women with childbearing potential 
x3 = Optional 
x2 = compliance to be greater than or equal to 75% 
*Study visits are defined by the period of time necessary to complete events described in the protocol and may span 
several days. 
10 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
All study visits may be performed in person at  the NIH CC or virtua lly using NIH approved 
TeleMedicine software and approved NIH TeleMedi cine guidance. In the event the subject is 
not able to come to the NIH CC the consent may be obtained by phone, vital signs are optional 
and reported based on subjectâ€™s own measurements  (if possible), physical exam is optional and 
none of these changes will be considered a prot ocol deviation. If there are remaining tablets, 
they will be returned to  the research team at first possible opportunity following NIH pharmacy 
direction. 
11 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
2 INTRODUCTION 
2.1 STUDY RATIONALE 
Over the past two decades, inflammation has been id entified as an important pathogenic process in 
cardiometabolic diseases (CMD) such as at herosclerotic cardiovascular disease (CVD), 
dyslipidemia, insulin resistance, diabetes and ob esity. Over the last eight years, the Mehta 
laboratory within the NHLBI DIR has studied psoriasis, a comm on, chronic inflam matory T-cell 
skin disease associated with increased CVD and CMD as a mode l to understand the effect of 
chronic inflammation on these disease states. At th e same time, the degree of obesity has been 
linked to the severity of psoriasi s and caloric restriction ameliora tes dermatologic manifestations 
of this disease. The Sack laboratory is studyi ng the effects of caloric  restriction on immune 
activation and is demonstrating the caloric-restriction mimetic v itamin B3 analogue nicotinamide 
riboside (NR) blunts both adaptive  and innate immunity. Furthermore, the in-vitro administration 
of NR to CD4+ T cells extracted from psoriatic subjects bl unts IL-17 production. Given this, these 
two laboratories will collaborate in a pilot study to evaluate wh ether the administration of a 
nutritional supplement NR has anti-inflammatory e ffects in a small cohort of subjects that have 
untreated mild to mo derate psoriasis. 
 
2.2 BACKGROUND 
Psoriasis is a chronic inflammatory  skin disease that affects 2â€“3% of the US population. In addition to 
its skin and joint manifestations, psoriasis predis poses to premature cardiovascular co- morbidities 
in part through immune activ ation and systemic inflamma tion-induced atherosclerosis.1, 2 The skin- 
initiated immune activation thr ough non-professional immune cells  including keratinocytes and 
fibroblasts, initiates and amplif ies innate and adaptive immune ac tivity of monocytes/macrophages, 
neutrophils and their subsets (low -density granulocytes), and effector T-cells (predominantly Th1 
and Th17 subsets) which concurrently exacerbate  local disease and init iate systemic sterile 
inflammation. The centrality of immune activation in psoriasis is reinforced by the therapeutic 
efficacy of anti-TNF D and anti-IL-17 therapy.3-5 
The contribution of caloric-load to psoriasis has been long debated, how ever, epidemiology and 
meta-analysis data support th at the incidence of obesity  is higher in psoriasis and that the greater the 
severity of psoriasis, the hi gher the incidence of obesity.6-8 The role of caloric excess in the 
pathophysiology of psoriasis is further strengthened  by the effects of limiting calories on disease 
activity.9-11 Taken together, these data support that nut rient levels may play a role in the 
pathophysiology of psoriasis and at the same t ime employing strategi es to mimic caloric 
restriction/fasting may contribu te to disease-amelioration. 
The Sack laboratory employs fasting as a model system to investigate immune cell function and 
have identified biological pathways that ex plain how fasting blunts immune activation in 
monocytes/macrophages and CD4+ T cells in both healthy subjects and in those with a mild 
inflammatory disease (steroid-naÃ¯ve asthma subj ects). More recently we have begun to explore the 
role of a caloric restriction/fasting mimetic , nicotinamide ribosi de (NR â€“ a vitamin B 3 analogue and 
precursor for NAD+ biosynthesis) on immune modulation. Our in itial clinic study using 1000 mg of 
NR daily blunted immune pathways importa nt in CVD both in monocytes and CD4+ T cells, however, 
we did not investigate the ef fects of NR on neutrophils. 
12
Abbreviated Title: NR in psoriasis
Version Date: 07/21/2023
Template version date 07-29-2019Given that these cell types contribute to the pathophysiology of psoriasis and that disease activity
may be ameliorated by dietary restriction, we reasoned that NR may blunt psoriasis-linked immuneactivation pathways. To explore this, a collaboration was established with the Mehta laboratory andthe in-vitro effects of NR were tested on CD4
+ T cells extracted from biologic treatment-naÃ¯ve
psoriatic subjects. NR was found to b OXQWWKHVHFUHWLRQRI,)1È–DQG,/ -17, predominantly Th1 and
Th17 cytokines respectively. Because these cytokines are instrumental in the progression of thedermatologic, systemic and vascular consequences in psoriasis, we propose a pilot interventionalstudy to explore the immunological consequences of NR supplementation in biologic naÃ¯ve, mild to
moderate psoriatic subjects.
Preliminary Data:
To study the effect of NR on T cell function, blood was drawn from psoriatic subjects enrolled
on protocol 13-H-0065 and from matched normal control subjects enrolled on protocol 16-H-0126. Psoriatic subjects were biological anti-immune therapy naÃ¯ve. Primary peripheral blood mononuclear 
cells (PBMCs) were isolated by density centrifugation. CD4
+ T cells were then negatively selected 
from PBMCs and cell purity was confirmed at > 95%. 
CD4+ T cells were activated in culture on plates coated with DCD3 and DCD28 antibodies for
3 days in the presence or absence of 0.5mM NR. Alternatively they were differentiated into two T
cell subtypes by incubation with the specific polarization media ( Â± NR) - Th1 (20 ng/ml IL-12 and
10 Pg/mlDIL-4) and Th17 (20 ng/ml IL-6, 2 ng/ml TGF- E1, 10 ng/ml IL-1 E, 10 ng/ml IL-23, 10 
Pg/ml DIL-4, and 10 Pg/ml DIFNJ). Supernatants were collected, centrifuged to remove cells and
debris, and stored at Ã­Âƒ& The levels of cytokines, including IL-1 E, IFNJ, IL-4, IL-5, IL-13, IL-17,
IL-22, IL-9, IL-2, and MIP-1 Ewere measured by ELISA (R&D Systems). Results were normalizedto
cell number using the CyQuant cell proliferation and BCA protein assays .
A 
5000
4000
3000B 
1500
1000
2000
1000500
0
PSC PS 0
PSC PS 
**
**
** *
*IFN  Release in Th0 cells (pg/ml)
IL-17 Release in Th0 cells(pg/ml)
13
Abbreviated Title: NR in psoriasis
Version Date: 07/21/2023
Template version date 07-29-2019
*
*
C                                                               D 
15000 5000
10000 
5000 4000 
3000 
2000 
1000 
0
PSC PS 0
PSC PS 
** *
**IFN  Release in Th1 cells (pg/ml)
IL-17 Release in Th17 cells (pg/ml)
14 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
Figure Legend: A, B. IFNJ and IL-17 release in activated CD4+T cells isolated from Psoriatic subjects (PS) and control 
subjects (PSC). CD4+T cells was activated with 0. 5 mM NR and 10% autologous serum for 3 days by DCD3 and 
DCD28 (n=7). C, D. IFNJ and IL-17 release in differentiated CD4+T cells isolated from Pso riatic subjects (PS) and 
control subjects (PSC). CD4+T cells was differentiated with 0.5 mM NR and specific differentiation media with 
autologous serum for 3 days by DCD3 and DCD28 (n=6). Th1 differentiation supplement (Stemcell Technologies), Th17 
differentiation supplement (R&D). PS age (y), 54.43Â±14.41 (range: 32-72); PS gender, 1 female and 6 males. Healthy 
volunteers (PSC) were paired with the psoriatic subjects for age (Â± 5 years) and sex. P value *<0.05 and **<0.01. 
 
These data show that NR blunts Th1 and Th17 activation in naÃ¯ve a nd differentiated T cells and that 
the psoriatic subjects exhibited elev ated IL-17 responsiveness, which is  a consistent signature of this 
disease. These findings supported the proposal of the following hypothesis. 
 
2.3 RISK/BENEFIT ASSESSMENT 
2.3.1 Known Potential Risks  
Niagen has been sold as a dietary supplement in the United States since 2003. Labeling guidelines 
recommend consumers to limit their intake to 2 capsules/day (250 mg/d ay). This recommended 
level is the equivalent of 3.8 mg/kg body weight/day, which is 1000-fold less than the highest 
dose determined to be safe and well tolerated in rats, and there is no limit on the duration of 
ingestion. 
 
There is extensive literature on the benefi cial effects of NR in animal models,12, 13 and multiple 
lines of non-clinical data suggest  that it should be well tolerated in human s ubjects. In an acute 
toxicology study, rats that were gi ven a single oral dose (5000 mg/kg)  of NR did not show clinical 
signs of toxicity or mortality (unpublished results). The NR dose pr oposed for this study is within 
the doses tested in mice for up to 4 months and is  300-fold below the daily dose that was given in 
rats in a 14-day dose range finder study. There are also accumulating data on the 
pharmacokinetics and safety of orally administe red NR in humans. Recently, a 2 x 6-week 
randomized, double-blind, cross-over study was performed  to assess the tolera bility of chronic NR 
supplementation and its efficacy for increasing NAD+ bioavailabilit y. Here the oral administration 
of NR 500 mg twice daily (total 1000 mg daily,  Niagen, ChromaDex, Inc.) was well tolerated, 
readily absorbed, and detectable in hu man plasma, white blood cells, and urine.14 In a 
pharmacokinetic study of 8 healthy volunteers at the University of Washington, Seattle, the oral 
dose of NR dose was escalated from 250 mg dail y to 1000 mg twice daily  over a 9-day period 
with a resultant 100% in crease in blood NAD+ content that highly correlated to NR levels.15 No 
adverse events were associated with NR treatment  in either of these two published human studies. 
 
Niacin is a form of vitamin B3 and has been used  to treat hypercholester olemia and pellagra for 
many years. Niacin administration ca n lead to undesirable effects such as spontaneous flushing, 
but based on its pharmacology, NR would not be  predicted to give this side effect.16, 17 Indeed, the 
incidence of flushing side effect  with NR treatment was not diffe rent compared with placebo in 
the double-blind study.18 Nicotinamide, an expected metabolite of  NR, is considered to be of low 
toxicity in food by several re gulatory agencies including the United States Food and Drug 
Administration (FDA) and the European Food Safe ty Authority (EFSA). Clinical trials of 
nicotinamide up to 3000 mg daily and 3 years in pa tients with or at risk of developing Type 1 
diabetes have not reported  significant adverse effects.19, 20 In addition, doses of 25 and 42 mg/kg 
body weight per day had no effect on a variety of biochemical parame ters including those 
assessing liver a nd kidney function. 
 
15 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 In summary, careful analysis of the available information on NR does not  reveal any potential 
serious toxicity that would preclud e its use in psoriasis subjects. Gi ven the safety and tolerability 
of NR in published human studies,18, 21 and the favorable experience with NR in our NHLBI DIR 
protocol (16-H-0129, discussed in Background section), we propose to test the effect of NR in 
psoriasis patients at a dose 500 mg  twice daily, a dose that is less than what is currently approved 
for use in other active clinical st udies of the aforementioned groups. 
 
The only tests and procedures done under this st udy are skin biopsies (o ptional), blood draws, 
and urine collection. The individual study procedure risks are listed below.  
Skin biopsy: Two 4mm or smaller biopsies ma y be collected at visit 1 and visit 2 for a total of 
four skin biopsies. This procedure will be perf ormed under local anesthesia . The entire procedure 
takes approximately 20 minutes. Discomfort at the biopsy site is usually mild and transient. This 
can be treated with minor analgesics. Normally, the risks include a reaction to the local anesthetic 
and the slight possibilities of loca l bleeding or infection. Scarring al ways occurs at the biopsy site. 
 
Phlebotomy: Standard precautions for obtaining human blood samples will be taken. Transient 
discomfort and minor bruising may occur at the phlebotomy site. Vasovaga l symptoms can occur 
during blood drawing. Blood samples will be obtain ed by venipuncture. The quantities of blood to 
be drawn for research purposes will be less than 550ml, which is consistent with the CC policy as 
provided in Medical Administrative Series (MAS) 95 -9 (revised 5/29/12): for adults, no more than 
10.5mL/kd or 550ml (whichever is smaller) will be drawn for research purposes over any 8 week 
period. 
 
Known Potential Benefits 
This supplement study has no pros pect of direct benefit. 
2.3.2 Assessment of Potential Risks and Benefits 
The risks of the study supplemen t and the minor procedures in cluded in this protocol are 
minimal and justified by the pot ential benefit of expanding our understanding of how nutrient 
levels may play a role in the pathophysiology of psoriasis and at th e same time employing 
strategies to mimic ca loric restriction/fasting may contri bute to disease-amelioration. This 
supplement has been employed at the same or higher doses in numerous  studies without any 
reported adverse effects.14, 18, 21 
 
3 OBJECTIVES AND ENDPOINTS 
 
OBJECTIVES ENDPOINTS JUSTIFICATION FOR 
ENDPOINTS 
Primary   
 The primary outcome will be the change NR blunts Th1 and Th17 
Evaluate the effect of NR on Th17 in the T H17 cell cytokine IL-17 secretion activation in naÃ¯ve and 
biology in response to T-cell differentiation 
comparing the baseline to NR response. differentiated T cells and 
psoriatic subjects exhibit 
  elevated IL-17 
  responsiveness, which is a 
  consistent signature of this 
16 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
   disease. 
Exploratory   
  The primary driver of 
psoriasis does appear to be 
OBJECTIVES ENDPOINTS JUSTIFICATION FOR 
ENDPOINTS 
Explore whether other inflammatory 
components linked to psoriasis are 
affected by NR.  
Evaluate the effect of NR on the T 
cell transcriptome 
 Explore the effect of NR on neutrophils, specifically low-density granulocytes 
 
 Th17, however, other 
immune signals and cell 
types are linked to psoriasis including, neutrophil 
activation, skin 
keratinocyte activation and the accumulation of HDL 
in monocytes/macrophages 
is proposed to trigger inflammatory pathways. 
We will explore the effect 
of NR on modulating these 
cell types and pathways as 
exploratory end points 
 
4 STUDY DESIGN 
4.1 OVERALL DESIGN 
This study is a pilot, prospective, two-arm doubl e-blind, placebo-controlled study where subjects 
immunological profile will be studi ed at baseline and following 4 weeks of supplementation with 
NR or placebo. The allocation of NR: placebo will be 2:1. All enrolled subjects  will receive NR or 
placebo and following 4 weeks of supplement or pl acebo intake, research parameters will be 
compared to baseline to determine the effects of this intervention. 
 
SCIENTIFIC RATIONALE FOR STUDY DESIGN 
This is a pilot study and the number of subjects were chosen to allow us to have sufficient 
samples to use RNAseq analysis to explore the effects of NR on T ce ll biology if the primary 
outcome of the study is confirmed. 
 
4.2 JUSTIFICATION FOR DOSE 
Recently, a 2 x 6-week randomized, double-blind, cr oss-over study was performed to assess the 
tolerability of chronic NR supplementation and it s efficacy for increasing NAD+ bioavailability 
by investigators at the University of Colorado, Boulder.14 They demonstrated that the oral 
administration of NR 500 mg tw ice daily (total 1000 mg dail y, Niagen, ChromaDex, Inc.) was 
well tolerated, readily ab sorbed, and detectable in human pl asma, white blood cells, and urine. 
17 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
5. STUDY POPULATION 
ELIGIBILITY ASSESSME NT AND ENROLLMENT 
All protocol eligibility criteria will be met be fore dispensing study medication to participants or 
conducting the biopsy for the baseline visit. Patients  will sign the consent prior to any screening 
tests/procedures done as part of this  protocol. 
 
5.1 INCLUSION CRITERIA 
Individuals must meet all inclusion criteria listed below in order to  be eligible to participate in 
the study. 
x Males and females between the ag es of 18 and 80 with mild to  moderate activ e psoriasis. 
x Female subjects of child-bearing ability willi ng to commit to reliable contraception while 
participating in the study. 
x Ability to provide informed consent 
x Willingness and ability to partic ipate in required study procedures 
 
5.2 EXCLUSION CRITERIA 
x Severe psoriasis by PASI (Psoriasis Area and Severity Index) score > 12 
x Currently being treated with bi ologic immune modifying agents. 
x Currently on treatment for allergies or other inflamma tory diseases. 
x  Currently taking a multivitamin, Vitamin B or  tryptophan supplementation and unwilling to stop 
within 2 weeks of baseline visit.. 
x Unwillingness/inability to pr ovide informed consent 
x ALT > x3 upper limit of normal, hepatic insufficiency or active liver disease 
x Recent history of acute gout 
x Chronic renal insufficiency with creatinine > 2.5mg/dl 
x Pregnant (or attempting to  become pregnant) women 
x Current participation in another drug study 
x History of intolerance to NR precursor  compounds, including niacin or nicotinamide 
x Study adherence concerns 
x Individuals with diabetes type 1 and 2 who use insulin 
x Women of child-bearing potential unwilling to  use contraception or  unwilling to practice 
abstinence 
x Breastfeeding women unwilli ng to stop breastfeeding 
x Immunization administered within 30 days of pa rticipation and no plan s for immunization while 
participating in the study 
 
5.3 INCLUSION OF VULNERABLE PARTICIPANTS 
Rationale for the Exclusion of Children 
Subjects under 18 years of age will not be considered for inclusion in  this protocol because there is 
no direct benefit from participa ting in this study and the volumes of blood levels drawn exceed 
18 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 minimal risk for children 
Rationale for the exclusion of pregnant women 
The subject must not be pr egnant or actively seeking pregnancy in  order to participate in this study. 
NR has not been determined to be safe in pregnancy or breastf eeding women. A rec ognized form of 
contraception must be used by subjects while en rolled. Contraception use will  be determined during 
telephone screening and confirme d at the screening visit. 
 
Rationale for the exclusion of cognitively impaired subjects 
Subjects with cognitive impa irment will not be considered for in clusion because there is no direct 
benefit from participa ting in this study. 
5.4 LIFESTYLE CONSIDERATIONS 
During this study, partic ipants are asked to: 
x Refrain from making major changes in dietary intake or  physical activity 
during the 6 weeks of acti ve study participation. 
 
5.5 SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently assigned to the study inte rvention. These subjects w ill sign consent and will 
receive a study id. 
Individuals who do not meet  the criteria for participation in this trial (screen failure) may be 
rescreened at a later date at PI discretion. Indi viduals who do not meet cr iteria for participation 
based on an abnormal laborator y test result may be resc reened after one month. 
Rescreened participants will be assigned a new pa rticipant id number from the initial screening. 
 
5.6 STRATEGIES FOR RECRUITMENT AND RETENTION 
Subjects with mild to moderate ps oriasis will be recruited from Dr. Mehtaâ€™s psoriasis clinic. We 
will also recruit subjects through NIH using traditio nal recruitment methods such as referrals from 
other protocols, outsi de physician referral and self-referral. 
With IRB approval the study may opt to use the fo llowing strategies for r ecruitment of patients: 
x ClinicalTrials.gov 
x Clinical Center Research Studies website 
x National Heart, Lung and Blood Institute (NHLBI) patient recruitment website 
x Twitter messages and chats with study investigators 
x Social Media posts 
x Use of CC Office of Patient Recruitm ent services including creation and 
distribution of study flyers  and information through pre-existing recruitment 
avenues such as the NIH recruitment listserv. 
19 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
We expect to screen up to 40 subjects with a goal of 27 subjects (18 NR + 9 placebo) completing 
the study. 
5.6.1 Costs 
There will be no anticipated costs that the subject will be responsible for. 
5.6.2 Compensation 
Subjects will be compensated for some of the pr ocedures that are perfor med since they may not 
provide direct benefit to the subject. They will be compensated by check or direct deposit at the end 
of the study or at the time of study withdrawal for the procedures  completed. Payment will typically 
be received within 2 months  of the last study visit. 
 
Procedures Convenience Units Compensation per 
procedure Frequency Total 
Compensation 
Medical History 2.5 $25.00 1 $25.00 
Screening Blood Draw (if needed) 1 $10 1 $10 
Research Blood Draw 5 $50.00 2 100.00 
Research skin biopsy 5 $50.00 4 $200.00 
Drug administration, General 2 $20.00 28 $560.00 
Maximum Compensation: $895.00 
 
Reimbursement for travel, food, and lodging will not be provided. 
 
6 STUDY INTERVENTION 
6.2 S TUDY INTERVENTIONS (S) ADMINISTRATION 
6.1.1 Study Intervention Description 
The study will use the dietary supp lement Nicotinamide Riboside or  a placebo capsule. NiagenÂ®is a 
commercially-available form of nico tinamide riboside (NR). The nucle oside NR is a single chemical 
moiety containing nicotinamide and ribose.22 NR is a form of vitamin B3 present in trace amounts in 
foods like milk, yeast extract and beer . It is also postulated that NR is generated inthe gastrointestinal 
tract as part of dietary NAD+. T hus, humans are constantly exposed to NR from the diet, albeit at 
low levels. Considering the clinic al investigation is designed to  study the relationship between a 
dietary supplementâ€™s effect on st ructure or function in humans or to characterize the mechanism by 
which a dietary supplement acts to maintain such structure or func tion, this study would not need to 
be conducted under an IND. Under the Dietary Supplement Health and Education Act of 1994, a 
dietary supplement is not considered  a drug and is not subject to the premarket approval requirements 
for drugs if the intended use for which it is marketed is only to affect the stru cture or any function of 
the body (i.e., not intended to be used for a therapeutic 
20 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
purpose). Similarly, whether an IND is needed fo r a clinical investigat ion evaluating a dietary 
supplement is determined by the inte nt of the clinical investigation. If the clinical in vestigation is 
intended only to evaluate the di etary supplementâ€™s effect  on the structure or function of the body, an 
IND is not required. 
 
6.1.2 Dosing and Administration 
N/A 6.1.3 Dose Escalation 
N/A 
6.1.4 Dose Limiting Toxicity 
N/A 6.1.5 Dose Modifications 
N/A 6.1.6 Drug Administration 
Subjects will take two capsules by mouth (250mg NR capsules or pl acebo) twice daily for a total 
of 4 weeks (+/- up to 5 days if needed). Capsules  must be taken whole and may be taken with or 
without food. Doses should be approximately 12 hours apart but there should be a minimum of 6 
hours between doses. If a dose is mi ssed and it is more than 6 hour s before the next dose is due 
then the dose can be taken. If a dose is missed and it is less than 6 hours be fore the next dose is 
due then the missed capsules should be skipped. 
 
6.2 PREPARATION/HANDLING/STO RAGE/ACCOUNTABILITY 
6.2.1 Acquisition and Accountability 
Both the NR and placebo will be obtained from Chro madex. It will be stored and dispensed by the 
NIH CC Pharmacy. Unused produc t will be returned to the cl inical center and destroyed. 
6.2.2 Formulation, Appearance, Packaging, and Labeling 
Common name: Nicotinamide Riboside Chloride 
Product name:  Niagen 
Chemical name:  3-(Aminocarbonyl)-1- È•-D-ribofuranosyl-pyridinium chloride (1:1) 
Daily dose:  1000 mg x 4 wk, 
Route of administration:  oral 
Dosing instructions:  500 mg (2 capsules) twice daily Supply: Su pplements will be obtained from Chromadex. 
Toxicology:  None known 
 
Drug Interactions:  None known 
The capsules will be put into individual bottle s, labeled and dispensed by the NIH Clinical 
Center pharmacy. The label will in clude at a minimum the study ID  and instructions for taking 
the supplement or placebo. 
The placebo will be manufactured and supplied by  Chromadex to match the active supplement. 
21 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 6.2.3 Product Storage and Stability 
NR and placebo will be stored in the pharmacy at room temperature in light restricted containers. 
6.2.4 Preparation 
N/A 
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 
Dr. Myron Waclawiw (BioStatistical Co-Investigat or on the study) will devise a randomization 
code . The code will be employed by the pharmacy to dispense the study pills. The study team will 
be blinded to the code until enrollment is comple te and the assays performed for the primary end 
point. 
6.4 STUDY INTERVENTION COMPLIANCE 
Study capsule compliance will be assessed based on patient report and we will perform capsule 
count at Visit 2. If Visit 2 takes pl ace remotely, the investigator wi ll observe the research subject 
counting the remaining pills. Blood NAD+ metabolic intermediate levels will be tested at visit 2 to 
confirm compliance. 
6.5 CONCOMITANT THERAPY 
Subjects should not take any biologic immune mo difying agents, other multivitamins, vitamin B 
or tryptophan supplements fo r the duration of the study. 
 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
7.1 Discontinuation Of Study Intervention 
The supplement has a good safety record and we do not expect any significant adverse events. 
However, if a grade 3 or higher adverse event re lated to the supplement occurs, the study will be 
halted pending discussions with the NIH IRB and the NHLBI Clinical Director. 
 
7.2 PARTICIPANT DISCONTINUATION /WITHDRAWAL FROM THE STUDY 
Participants are free to withdr aw from participati on in the study at any time upon request. 
An investigator may discontinue or withdraw  a participant from the study for the following 
reasons:  
1) Subject taking less than 75% of their capsules 
2) Subject found to be pregnant or  wishes to breastfeed duri ng the study will automatically 
be withdrawn 
3) If subject no longer wi sh to participate 
4) Subjectâ€™s non-compliance or pe r PI discretion for developmen t of a condition that may 
independently affects immune activity. 
Prior to removal from study, any subject who has st arted the study interventi on should complete a 
safety visit. For subjects who co mplete the study, this would be in cluded in Visit 2. If a subject 
requests withdrawal early for any reason, we will make every effort  to have them complete an 
22 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 unscheduled safety visit.. 
The reason for participant discontinuation or with drawal from the study will be recorded in the 
source document. Subjects who sign the inform ed consent form and are randomized but do not 
receive the study intervention may be replaced. Subjects who sign the in formed consent form, 
and are randomized and receive the study inte rvention, and subsequently withdraw, or are 
withdrawn or discontinued from the study, will be  replaced until the recru itment goals of 18 NR 
and 9 placebo subjects have completed the protocol . Participants who are withdrawn for reasons 
that are temporary, such an infectious disease or administration of an  immunization, may be re- 
screened and if they meet  eligibility then re-enr olled with a new study id. 
 
7.3 LOST TO FOLLOW-UP 
A participant will be considered lo st to follow-up if he or she fa ils to return for the scheduled 
visits and is unable to be contacted by the study site staff. 
The following actions must be taken if a participan t fails to return to the clinic for a required 
study visit: 
x The site will attempt to contact the particip ant and reschedule the missed visit, specify 
time frame and counsel the pa rticipant on the importance of  maintaining the assigned 
visit schedule and ascertain if  the participant wishes to an d/or should continue in the 
study. 
x Before a participant is  deemed lost to follow-up, the i nvestigator or designee will make 
every effort to regain contact with the participant (where possi ble, 3 attempts at contact) 
These contact attempts should be  documented in th e participantâ€™s medi cal record or study 
file. 
x Should the participant continue to be unreachab le, he or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. 
 
8 STUDY ASSESSMENTS AND PROCEDURES 
8.1 SCREENING PROCEDURES 
Subjects with mild to moderate psoriasis will be r ecruited from Dr. Mehtaâ€™s psoriasis clinic at the 
NIH or from outside and self- referrals If a subject is recruited from a source outside the NIH then the screening and/or baseline visi t #1 will be in person. The remai nder of the visits may be via 
telehealth.
 
Screening activities performed prio r to obtaining informed consent 
Minimal risk activities that may be performed befo re the subject has signed a consent include the 
following: 
â€¢ Email, written, in person or telephone communications with prospective subjects 
â€¢ Review of existing medical records to include H&P, laboratory studies, etc. 
 
Once the research team has identifi ed a potential subject for the study,  the subject will be asked to 
come to the NIH or complete a Te lehealth Screening Visit. The st udy team will cons ent the subject, 
allowing time for the subjects to ask que stions and make a voluntary decision. 
 
23 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 Once the subject signs the consent, the following te sts will be done at the Screening Visit unless any 
of the tests have been performed under another NI H protocol 2 weeks prior to signing the consent 
(unless otherwise stated). 
 
Screening Visit (May be combined with Visit 1): 
o Basic Metabolic Panel 
o Hepatic Panel + uric acid 
o CBC + Differential 
o Serum pregnancy test for women with chil dbearing potential (within the past 24 
hours) 
o History +/- physical exam ( physical exam will not be perfo rmed at TeleHealth visit) 
 
8.2 EFFICACY ASSESSMENTS 
This study is designed to study th e relationship between a dietary supplementâ€™s effe ct on structure 
or function in humans or to characterize the mechanism by which a diet ary supplement acts to 
maintain such structure or function. It is not desi gned as an efficacy study. Therefore, visits will 
focus on safety assessments as well as the collection of research blood and skin biopsies 
(optional). These collections will be performed  at the NIH CC phlebotomy department when 
feasible however collection at an  outside laboratory, such as a commercial or hospital-based lab, 
may be arranged if needed. 
8.2.1 Clinical Evaluations 
Radiographic or other imaging assessments. N/A 8.2.2 Biospecimen Evaluations 
Biological specimen collection and laboratory evaluations . In addition to the clinical blood 
samples, subject will have research bloods dr awn within the blood w ithdrawal volume limits 
established by the Clinical Ce nter. RNAseq, Flow cytometry, metabolomics, HDL cholesterol 
uptake and cytokine profiling may be performe d. Skin biopsy samples may be obtained for 
culture or isolation of distinct  cell populations for subsequent biochemical, cell biological and 
molecular analyses and for immune-histochemistry. With the patientâ€™s consent, a biopsy each of 
lesional skin (where there is active psoriasis) an d non-lesional sites (where  there is no psoriasis) 
will be performed, and hemostasis will be achieved. The skin biopsy will be performed by a healthcare provider and will be used primarily for research purposes. 
24 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
Test/assay Volume blood 
(approx.) Type of 
tube Collection 
point (+/- 48hrs) Location of 
specimen analysis 
Immune- monitorin g 80 mls for 
PBMCâ€™s and NAD+. Green Tops for 
PBMCâ€™s and NAD+ Baseline and 
4 weeks. 10-CRC, 
Room 5-3216 Lab 
(Deliver to Dr. Sackâ€™s lab) 
  
20mls for Neutrophils.  
Green Tops for Neutrophils  
  
20mls for low density granulocytes (LDGâ€™s).  
Green Tops for LDGâ€™s  
 5-10mls (for serum) Red top  
HDL 
reverse transport 2mls Purple top Baseline and 
4 weeks Dr. Mehta lab 
 
8.2.3 Correlative Studies for Research/Pharmacokinetic Studies 
N/A 8.2.4 Samples for Genetic/Genomic Analysis 
N/A 
 
8.3 SAFETY AND OTHER ASSESSMENTS 
Laboratory tests will be assessed at  baseline and at 4 weeks. Adverse event review will occur at 4 
weeks. 
Counseling: Subjects should maintain a stable diet a nd not start any new diets or exercise 
programs for the durat ion of the study.  
8.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
8.4.1 Definition of Adverse Event 
Adverse event means any untoward medical oc currence associated with the use of an 
intervention in humans, whether or not consid ered intervention-rela ted (21 CFR 312.32 (a)). 
8.4.2 Definition of Serious Adverse Events (SAE) 
25 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 An adverse event (AE) or suspected adverse reacti on is considered "serious " if, in the view of 
either the investigator, it results in any of the following outcomes: death, a life-threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantia l disruption of the ability to c onduct normal life functions, or a 
congenital anomaly/birth defect. Im portant medical events that ma y not result in death, be life- 
threatening, or require hospitaliz ation may be considered seri ous when, based upon appropriate 
medical judgment, they may jeopardize the part icipant and may require medical or surgical 
intervention to prevent one of th e outcomes listed in this defin ition. Examples of such medical 
events include allergic bronchospa sm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do no t result in inpatient hospitalization, or the 
development of drug depe ndency or drug abuse. 
8.4.3 Classification of an Adverse Event 
8.4.3.1  Severity of Event 
This study will utilize the Common Terminology Cr iteria for Adverse Events version 5.0 (CTCAE 
v5.0) for toxicity and adverse ev ent reporting. A copy of the CTCA E v5.0 can be downloaded from 
the https://ctep.cancer.gov/ protocolDevelopment/electr onic_applicati ons/ctc.htm. 
AEs classified as Grade 2-5 will  be recorded, verified, and follo wed until satisfactory resolution or 
stabilization. In the event of any treatment-rel ated SAEs, enrollment will be suspended until 
discussed with the IRB and Clinical Director.  Grading and attribution of adverse events 
Severity definitions found in the CTCAE v5.0 will be  used for grading the severity (intensity) of 
AEs: 
1) Mild : Asymptomatic or mild symptoms; clin ical or diagnostic observations only; 
intervention not indicated. 
2) Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate 
instrumental ADL* 
3) Severe: Severe or medically significa nt but not immediately life- threatening; hospitalization 
or prolongation of hospitaliza tion indicated; disabling;  limiting self -care ADL**. 
4) Life- threatening: Life-threatening consequences; urgent intervention indicated. 
5) Death: Death related to AE. 
 
*Instrumental ADL refer to prep aring meals, shopping for groc eries or clothes, using the 
telephone, managing money, etc.  
**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
 
8.4.3.2  Relationship to Study Intervention 
â€¢ All Grade 2-5 adverse events (AEs) must have  their relationship to study intervention 
assessed by the investigator or designee who examines a nd evaluates the participant 
based on temporal relationship and his/her cl inical judgment. The degree of certainty 
26 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 about causality will be graded using the cate gories below. In a clinical trial, the study 
product must always be suspect. 
â€¢ Definitely Related â€“ There is clear evidence to suggest  a causal relationship, and other 
possible contributing factors can  be ruled out. The clinical event, including an abnormal 
laboratory test result, occurs in a plausi ble time relationship to study intervention 
administration and cannot be explained by concurrent disease or other drugs or 
chemicals. The response to withdrawal of the study intervention (dechallenge) should be 
clinically plausible. The event must be pharmacologically or phenomenologically 
definitive, with use of a satisfactory rechallenge procedure if necessary. 
â€¢ Probably Related â€“ There is evidence to suggest a causal relationship, and the influence 
of other factors is unlikely. The clinical event, including an abnormal laboratory test 
result, occurs within a reasonable time afte r administration of th e study intervention, is 
unlikely to be attributed to concurrent diseas e or other drugs or chemicals, and follows a 
clinically reasonable response on withdrawal (dechallenge). Rechallenge information is 
not required to fulfi ll this definition. 
â€¢ Potentially Related â€“ There is some evidence to sugge st a causal relationship (e.g., the 
event occurred within a reas onable time after administration of the trial medication). 
However, other factors may have  contributed to the event (e. g., the participantâ€™s clinical 
condition, other concomitant events). Although an  AE may rate only as â€œpossibly relatedâ€ 
soon after discovery, it can be flagged as requiring more information and later be 
upgraded to â€œprobably relatedâ€ or â€œd efinitely relatedâ€ , as appropriate. 
â€¢ Unlikely to be related â€“ A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to study in tervention administration makes a causal 
relationship improbable (e.g., the event did no t occur within a re asonable time after 
administration of the study intervention) a nd in which other drugs or chemicals or 
underlying disease provides plausible explan ations (e.g., the part icipantâ€™s clinical 
condition, other concom itant treatments). 
â€¢ Not Related â€“ The AE is completely independent of study interventi on administration, 
and/or evidence exists that the event is defin itely related to another etiology. There must 
be an alternative, definitive e tiology documented by the clinician.] 
 
8.4.3.3  Expectedness 
The PI or designee will be responsible for determin ing whether an adverse event (AE) is expected 
or unexpected. An AE will be considered unexpected if the nature, severity, or 
 
frequency of the event is not consistent with the risk informat ion previously described for the study 
intervention. We expect some vasovagal symptoms during blood draws (expected frequency 50%) 
and transient bruising at the site of blood draws (expected frequency 50%). 
 
8.4.4 Time Period and Frequency for Event Assessment and Follow-Up 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the 
attention of study personnel duri ng study visits and interviews of  a study participant presenting 
for medical care, or upon review by a study monitor. 
27 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 Investigators will assess the occurrence of AEs and SAEs at all patient evaluation time points 
during the study. Grade 2 â€“ 5 AEs/SAEs whethe r volunteered by the patient, discovered by study 
personnel during questioning, or de tected through physical examin ation, clinically  significant 
laboratory test, or other means will be recorded on the appr opriate case report form. .  
Information to be collected on Grade 2-5 AE/S AE includes event descri ption, time of onset, 
clinicianâ€™s assessment of severity, relationship to study product (assesse d only by those with the 
training and authority to make a diagnosis), and time of resoluti on/stabilization of the event. All 
Grade 2-5 AEs will be followed to ad equate resolution or stabilization. 
Abnormal laboratory values not associated with clinical symptoms ( except  for grade 2 elevated liver 
enzymes)  will be evaluated but will not be       considered an AE. The laboratory results will be 
monitored by healthcare professionals and documented if  clinically significant by the MD or any AIs 
in the study. 
Psoriasis is a chronic disease associated with flares and we will record this information in 
the medical record. 
Any medical condition that is pres ent at the time that the part icipant is screened will be 
considered as baseline and not reported as an AE. However, if the study participantâ€™s condition 
deteriorates at any time during the study, it will be recorded as an AE. 
Changes in the severity of an AE will be documen ted to allow an assessment of the duration of 
the event at each level of severity to be perfo rmed. AEs characterized as  intermittent require 
documentation of onset and duration of each episode. 
The PI or designee will record all reportable ev ents with start dates occurring any time after 
informed consent is obtained until 7 days (for non-serious AEs or SA Es) after the last day of study 
participation. At each study visit,  the team member will inquire about the occurrence of AE/SAEs 
since the last visit. Events will be followe d for outcome information until resolution or 
stabilization.  
8.4.5 Adverse Event Reporting 
Grading and attribution of AEâ€™s captured in the database will be determined by the Principal 
Investigator or Associat e Investigatorâ€™s designat ed on the designation log. 
 
8.4.6 Serious Adverse Event Reporting 
The study investigator will immediately report to the NHLBI Clinical Director any serious 
adverse event, whether or not considered study intervention related, incl uding those listed in the 
protocol and must include an a ssessment of whether there is a reasonable possibility that the 
study intervention caused the event. 
All serious adverse events (SAEs) will be followe d until satisfactory resolution or until the site 
investigator deems the event to be ch ronic or the participant is stable. 
Any SAE considered at least pos sibly related to the supplement will be reported to the DSMB 
within 14 days of the investigat or being notified of the event. 
8.4.7 Events of Special Interest 
N/A 
 
NIH Intramural IRB and NHLBI Clin ical Director (CD) Reporting  
28 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
Expedited Reporting 
Events requiring expedited reporting will be  submitted to the IRB per HRPP Policy 801 
â€œReporting Research Eventsâ€. 
 
Reports to the IRB at the time  of Continuing Review (CR): 
The PI or designee will refer to HRPP Policy 801 â€œReporting Re search Eventsâ€ to determine 
IRB reporting requirements. 
 
Reports to the CD: 
The PI or designee will refer to NHLBI DIR guide lines to determine CD reporting requirements 
and timelines. 
 
8.4.8 Reporting of Pregnancy 
If pregnancy occurs during the course of this study a reportable event form will be submitted to 
the Clinical Director and the IRB. 
Pregnancy itself is not regarded as an SAE unless there is susp icion that the investigational 
product under study may have interf ered with the effect iveness of a contraceptive medication. 
Any SAEs associated with pregnancy (i.e. c ongenital abnormalities/bi rth defects/spontaneous  
miscarriages or any other serious events) must additionally be reported as such using the SAE 
report form. Monitoring of the pregnancy thr ough chart review (per HIPPA guidelines) will 
continue until conclusion of the pregnancy, and then subject will be taken off study. 
8.5 UNANTICIPATED PROBLEMS 
8.5.1 Definition of Unanticipated Problems (UP) 
Please refer to Policy 801 for current Definitions. Any incident, experience, or outcome that meets all of the following criteria: 
â€¢ Unexpected in terms of nature, severity, or  frequency given (a) the research procedures 
that are described in the prot ocol-related documents, such  as the Institutional Review 
Board (IRB)-approved research protocol and informed cons ent document; and (b) the 
characteristics of the particip ant population be ing studied; and 
â€¢ Related or possibly related to participation in the research (â€œpossibly relatedâ€ means there 
is a reasonable possibility that the incide nt, experience, or ou tcome may have been 
caused by the procedures invol ved in the research); and 
â€¢ Suggests that the research places participants  or others (which many include research 
staff, family members or other individuals not directly partic ipating in the research) at a 
greater risk of harm (incl uding physical, psychological, econ omic, or social harm) than 
was previously known or expected. 
8.5.2 Unanticipated Problem Reporting 
The investigator will report unan ticipated problems (UPs) to the NIH Institutional Review Board 
29 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 (IRB) as per Policy 801. 
8.5.3 NIH Intramural IRB Reportin g of IND Safety Reports 
N/A 
 
9 STATISTICAL CONSIDERATIONS 
9.1 STATISTICAL HYPOTHESIS 
Supplementation with NR will blunt systemic imm une activation in mild/moderate psoriasis. 
 
Primary Endpoint(s): The primary ou tcome will be the change in the T H17 cell cytokine IL-17 
secretion in response to T-cell di fferentiation comparing the baseline to NR response after 28 days. 
Exploratory Endpoint(s): 
o Evaluate the effect of NR  on the T cell transcriptome 
o Explore the effect of NR on low-de nsity granulocytes and neutrophils 
9.2 SAMPLE SIZE DETERMINATION 
Sample size calculations for this pilot study were  based on the two-sample  t-test assuming equal 
variances with a two-sided alpha of 0.05 and a 2:1 (unequal) alloca tion of subjects NR: placebo. A 
previous in-vitro study (unpublished to data) yields  data for IL-17 levels  (pg/ml) for T-cells 
extracted from psoriatic subj ects at baseline and after 72 hours of exposure to 0.5 mM 
nicotinamide riboside (NR). The observed mean ch ange in IL-17 cytokine release was 329 pg/ml 
(from 600 to 271 pg/ml) with a stan dard deviation of 185.74 for the 72-hour changes. For the 
proposed in-vivo study, we assume a similar change in mean IL- 17 (and standard deviation) for 
psoriatic subjects treated with NR for 4 weeks. For the control subjects receiving placebo, we 
assume a mean baseline to 4 weeks change in IL-17 of 0 and an equal standard deviation of 
185.74 for the 4-week changes. 
 
In the table below, we present power calculations  for various scenarios.  With 18 subjects on NR 
and 9 on placebo, the study will have 98% power to  detect a difference of  329 pg/ml in the mean 
baseline to 4-week changes between the two study groups (scenario 1). Note that there will still be 
82% power to detect a smaller mean differenc e of 229 pg/ml between the two study arms (a 100 
pg/ml difference less than that achieved in the in -vitro study) should the control subjects exhibit 
up to a 100 pg/ml decrease in IL-17 due to a placebo effect (scenario 2). Furt hermore, even with a 
loss to follow-up of 3 subjects (2 in the NR ar m, 1 on placebo), the study will have 97% power to 
detect a mean change of 329 pg/ml (scenario 3), and a reduced power just under 80% for a strong 
placebo effect with a mean  difference = 229 pg/ml (scenario 4). Therefore, we request approval to 
screen up to a total of 40 subjec ts to account for po ssible treatment non- co mpliance and/or study 
dropouts (18 NR + 9 placebo completi ng study) and to achieve the obj ectives of this pilot study. 
 
Scenario  1 2 3 4 
#Subjects treated with NR 18  18 16 16 
# subjects on placebo 9 9 8 8 
Difference in means 329 229 329 229 
Power 98% 82% 97% 77% 
 
30 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
9.3 POPULATIONS FOR ANALYSES 
N/A 9.3.1 Evaluable for toxicity 
All patients will be evaluable fo r toxicity from the time of th eir first treatment with study 
supplement or placebo. 
9.3.2 Evaluable for objective response 
N/A 
9.4 STATISTICAL ANALYSES 
9.4.1 General Approach 
9.4.2 Analysis of the Primary Endpoints 
The primary outcome will be the change in the T
H17 cell cytokine IL-17 secretion in response to T- 
cell differentiation compar ing baseline levels vers us their respective respon se to NR or placebo. The 
comparisons will be performed using paired two-tailed Student t-tests or if the data is not normally distributed, by the Wilcoxon test. Significance will be tested at the 0.05 alpha le vel in this pilot study. 
9.4.3 Analysis of the Secondary Endpoint(s) 
N/A 
9.4.4 Safety Analyses 
N/A 
9.4.5 Baseline Descriptive Statistics 
N/A 
 
10 REGULATORY AND OPERATIONAL CONSIDERATIONS 
 
10.1 INFORMED CONSENT PROCESS 
 
10.1.1  Consent/Assent Procedures and Documentation 
Informed consent will be conducted follo wing OHSRP Policy 301- Informed Consent. 
An IRB-approved consent form will  be provided to the participan t electronically or by hard 
copy for review prior to consenting. The initial consent process as well as re-consent, when 
required, may take place in person or remotely (e.g., via telephone or other NIH approved 
platforms). The investiga tional nature and objecti ves of this trial, th e procedures, and their 
attendant risks and discomforts and potential be nefits will be carefu lly explained to the 
participant in a private setting. The participant will be given as much time as they need to 
review the document and to c onsult with their family, friends , and personal health care 
providers. In addition, a study team member wi ll be available to answer any questions. 
A signed and dated informed consent document will be obtained by any investigator authorized 
to consent (See Key Study Personnel Page) prio r to entry onto the study. Consent may be 
obtained with required signatures on the hard co py of the consent  or on the electronic 
31 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 document.   
When a document that is in electronic format is used for obta ining  consent, this study may use 
the iMed platform which is 21 CFR, Part 11 compliant, to obtain th e required signatures. 
During the consent process, participants and inve stigators may view the same approved consent 
document simultaneously when participant is bei ng consented in person at the Clinical Center 
or both may view individual c opies of the approved consent document on screens in their 
respective locations remotely. Signatures may be  obtained either by both directly signing on the 
device that the consenting investigator is us ing (when in person) or  through iMed Mobile 
Signature Capture  (remotely) which allows texti ng or emailing a link to the participant. That 
link allows the participant to review the consen t, then proceed to si gn on the device they are 
using. 
Whether hard copy or electronic, both the i nvestigator and the participant will sign the 
document with a hand signature us ing a pen (if using hard copy), finger, stylus, or mouse (if 
electronic). 
When done remotely, if the partic ipant prefers to sign a hard c opy, they may be instructed to 
sign and date the consent docum ent during the discussion and ma il, secure email or fax the 
signed document to the c onsenting investigator. 
Whether in person or remotely, the privacy  of the participant will be maintained. 
Finally, the fully signed informed consent documen t will be stored in the electronic medical 
record, and the participant will receive a copy of the signed informed consent document.  
The informed consent process will be documented on  a progress note. The date th e signed informed consent 
document was received from the subject and signed by th e consenting investigator w ill be documented in the 
consent progress note.  
10.1.2  Consent for minors when they  reach the age of majority 
 
N/A 
 
10.1.3  Telephone consent 
Informed consent may be obtained over the telephone or by teleme dicine/videocall rather than 
in person. Informed consent will be obtained pe r HRPP Policy 301. Subjects will be contacted 
by telephone by the PI or AIs approved to obtain consent. The consent process obtained by the 
phone or videocall will be identical to a consen t obtained in person. The investigational nature 
and research, objectives of the trial, procedures, risks and di scomforts will be carefully 
explained to the subject. If the subject(s) choose(s) to particip ate, a signed informed consent 
will be obtained. The subject will sign and date the informed consent. The informed consent 
document may then be faxed, sent via NIH secure email, and will be  mailed back to either the 
investigator or to an authorized team member . The PI or AI approved to obtain consent will 
then sign and date the received consent. The orig inal consent will be sent to medical records. 
The informed consent process will then be docum ented in CRIS. At this point the subject will 
be considered enrolled in the study. The subjec t will receive a copy of th e signed consent either 
by FAX, secure e-mail, mail or by hand, at his first visit to th e CC for this study. 
10.1.4  Participation of Subjects who are/become Decisionally Impaired 
32 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 N/A 
10.1 STUDY DISCONTINUATION AND CLOSURE 
This study may be temporarily suspended or prem aturely terminated if there is sufficient 
reasonable cause. If the study is prematurely termin ated or suspended, the Principal Investigator 
(PI) will promptly inform study participants, the Institutional Review Board (IRB), and will 
provide the reason(s) for the te rmination or suspension. Study part icipants will be contacted, as 
applicable, and be informed of changes to study visit schedule. 
Circumstances that may warrant termination or  suspension include, but  are not limited to: 
x Determination of unexpected, significant, or unacceptable risk to participants 
x Insufficient compliance to  protocol requirements 
x Data that are not sufficiently complete and/or evaluable 
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the IRB. 
 
10.2 CONFIDENTIALITY AND PRIVACY 
 
Participant confidentiality and privacy is strictly held in trust by the participating investigators, 
their staff. This confidentiality is extended to co ver testing of biological samples in addition to 
the clinical information relati ng to participants. Therefore, the study protocol, documentation, 
data, and all other information generate d will be held in strict confidence. 
All research activities will be conducted in as privat e a setting as possible. 
The study monitor, other authorized representati ves of the sponsor, representatives of the 
Institutional Review Board (IRB) , and/or regulatory agencies may inspect all documents and 
records required to be maintained by the inve stigator, including but not limited to, medical 
records (office, clinic, or hosp ital) and pharmacy records for the participants in this study. The 
clinical study site will pe rmit access to such records. 
The study participantâ€™s contact info rmation will be securely stored  at the NIH for internal use 
during the study. At the end of the study, all records will continue to be kept  in a secure location 
for as long a period as dictated by the review ing IRB, Institutional policies, or sponsor 
requirements.  
Study participant research data, wh ich is for purposes of statis tical analysis and scientific 
reporting, will be stored in a research database in  conformity with NHLBI DIR policy. Individual 
participants and their research  data will be identified by a unique study identification number. 
The study data entry and study management system s used by clinical si tes and by the research 
staff will be secured and password protected. 
To further protect the privacy of study participants , a Certificate of Confidentiality has been issued 
by the National Institutes of Health (NIH). Th is certificate protects identifiable research 
information from forced disclosure. It allows th e investigator and others  who have access to 
research records to refuse to disclose identifying information on research participation in any civil, 
criminal, administrative, legislativ e, or other proceeding, whether at  the federal, state, or local 
level. By protecting researchers and institutions from being compelled to disclose information that would identify research participants, Certificates  of Confidentiality help achieve the research 
objectives and promote participatio n in studies by helping assure confidentiality and privacy to 
33 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 participants. 
 
10.3 FUTURE USE OF STORED SPECIMENS AND DATA 
We may share specimens and data with other researchers for future use. 
Following analyses of biospecimens  for primary research purposes as described in the protocol, 
remaining samples suitable for future research w ill be stored in manner that conforms with DIR 
policy (such as BSI) or in a publicly accessible re search biospecimen repository following IRB 
approval. Biospecimens may be destroyed only when permitted by the cl inical director and 
approved by the IRB. Any future research use of biospecimens not de fined in the research 
protocol will occur only after IRB review and approval, if th e research holds the key that 
identifies research subjects, or determina tion from OHSRP (non-coll aborative research). 
 
10.4 SAFETY OVERSIGHT 
Safety oversight will be under the direction of a Data and Sa fety Monitoring Board (DSMB) 
composed of individuals with the appropriate expertise. Members of the DSMB should be 
independent from the study conduct a nd free of conflict of interest, or measures should be in place 
to minimize perceived conflict of  interest. The DSMB will meet at least semiannually to assess 
safety and efficacy data on each  arm of the study. The DMSB w ill operate under the rules of an 
approved charter that will be wr itten and reviewed at the organi zational meeting of the DSMB. At 
this time, each data element that the DSMB needs to asse ss will be clearly defined. 
The DSMB will provide its input to Na tional Institutes of Health staff. 
 
10.5 CLINICAL MONITORING 
The monitoring of this study will  be conducted by clinical resear ch associates (CRAs)/monitors 
employed by an independent contract organiza tion working under an agreement with NHLBI to 
monitor aspects of the study in accordance with the appropr iate regulations and the approved 
protocol. The objectives of a monito ring visit will be: 1) to verify the existence of signed informed 
consent form (ICF) and documentati on of the ICF process for each mo nitored subject; 2) to verify 
the prompt and accurate recording of all monitored data  points, and prompt reporting of all SAEs;  
3) to compare abstracted info rmation with individua l subjectsâ€™ records and source documents 
(subjectâ€™s charts, laboratory analys es and test results, physiciansâ€™ pr ogress notes, nu rsesâ€™ notes, and 
any other relevant original subj ect information); and 4) to help ensure investigators are in 
compliance with the protocol. The monitors also w ill inspect the clinical si te regulatory files to 
ensure that regulatory requirements (Office for Hu man Research Protections-OHRP) and applicable 
guidelines (ICH-GCP) are being followed. Monito ring will be conducted according to the OCD 
schedule. During the monitoring visits, the investig ator (and/or designee) and other study personnel 
will be available to discuss the study progress and monitoring visit. 
The investigator (and/or designe e) will make study documents (e.g., consent forms and pertinent 
hospital or clinical records readil y available for inspection by the local IRB, the site monitors, and 
the NHLBI staff for confir mation of the study data. 
 
10.6 QUALITY ASSURANCE A ND QUALITY CONTROL 
34 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 Quality control (QC) procedures will be implement ed beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution. 
Following written Standard Operating Procedures (SOPs), the monitors will verify that the 
clinical trial is conducted a nd data are generated and biol ogical specimens are collected, 
documented (recorded), and reported in complian ce with the protocol, In ternational Conference 
on Harmonisation Good Clinical Pr actice (ICH GCP), and applicab le regulatory requirements 
(e.g., Good Laboratory Practices (GLP), Good Manufacturing Pr actices (GMP)). 
The investigational site will provid e direct access to all trial relate d sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and 
regulatory authorities. 
 
10.7 DATA HANDLING AND RECORD KEEPING 
10.8.1  Data Collection and Management Responsibilities 
Data collection is the res ponsibility of the clinical  trial staff at the site  under the supervision of 
the site investigator. The investigator is res ponsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported. 
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. 
Data recorded in the electronic case report form (eCRF) derived from source documents should 
be consistent with the data r ecorded on the source documents. 
Clinical data and clinical laborat ory data will be entered into CTDB, a 21 CFR Part 11-compliant 
data capture system. Clinical data will be entered directly from the source documents. 
10.8.2  Study Records Retention 
Study documents should be retained for a mini mum of 2 years after th e last approval of a 
marketing application in an International C onference on Harmonisation (ICH) region and until 
there are no pending or contemplated  marketing applications in an ICH region or until at least 2  
years have elapsed since the formal disconti nuation of clinical development of the study 
intervention, or as per the NIH Intramural R ecords Retention Schedule. No records will be 
destroyed without the written consen t of the NHLBI C linical Director. 
 
 
10.8 PROTOCOL DEVIATIONS 
It is the responsibility of the investigator to use continuous vi gilance to identify and report 
deviations to the NIH Institutiona l Review Board as per Policy 801. 
NIH Definition of Pr otocol Deviation 
A protocol deviation is any ch anged, divergence, or departure from the IRB-approved research 
protocol. 
x Major deviations: Deviations fr om the IRB approved protocol that have, or may have the 
potential to, negatively impact  the rights, welfare or safe ty of the subject, or to 
substantially negatively imp act the scientific integrity  or validity of the study. 
35 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 x Minor deviations: Deviations that do not have the potenti al to negatively impact the 
rights, safety or welfare of subjects or others, or the scientific integrity or validity of the 
study. 
 
10.9 PUBLICATION AND DATA SHARING POLICY 
10.10.1  Human Data Sharing Plan 
This study will be conducted in accordance w ith the following publication and data sharing 
policies and regulations: 
National Institutes of Health (N IH) Public Access Policy, which en sures that the public has access 
to the published results of NIH funded research. It requires scientists to submit final peer- 
reviewed journal manuscrip ts that arise from NIH funds to the digital archive PubMed Central 
upon acceptance for publication. 
This study will comply with the NIH Data Shar ing Policy and Policy on the Dissemination of 
NIH-Funded Clinical Trial Information and th e Clinical Trials Registration and Results 
Information Submission rule. As such, this tria l will be registered at ClinicalTrials.gov, and 
results information from this trial will be s ubmitted to ClinicalTria ls.gov. In addition, every 
attempt will be made to publish results in peer-review ed journals. Study participants may be 
notified by mail or secure em ail when results are posted on Clinicaltrials.gov or when a 
manuscript is posted. Data from th is study may be requested from other researchers 3 years after 
the completion of the primar y endpoint by contacting Dr. Mi chael Sack at the NHLBI 
10.10.2  Genomic Data Sharing Plan 
N/A 10.10   COLLABORATIONS AND AGREEMENTS 
10.11.1 Agreement Type  CRADA:  A CRADA between NHLBI and Chro madex for the conduct of this study is  being executed. 
 
MTA:  We will send coded PBMC for analysis of meta bolic pathways to Kennedy Institute, Oxford 
University UK (Dr. Alexander Clarke).  The collaborator will not have ac cess to the code key.  Upon receipt 
of the data analysis, NHLBI will link the analyzed da ta to identifiers. We will not send samples outside 
NIH without an executed material  transfer agreement (MTA). 
 
10.11   CONFLICT OF INTEREST POLICY 
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical. Therefore, any actual conflict of intere st of persons who have 
a role in the design, conduct, analysis, publication, or any aspect of this tr ial will be disclosed and 
managed. Furthermore, persons who have a perceived conflict of interest w ill be required to have 
such conflicts managed in a way th at is appropriate to their par ticipation in the design and conduct 
of this trial. The study leadersh ip in conjunction with the NHLBI  has established policies and 
procedures for all study group member s to disclose all conflicts of  interest and will establish a 
mechanism for the management of all reported dualities of interest. 
36 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
  
11 ABBREVIATIONS 
 
AE Adverse Event 
ANCOVA Analysis of Covariance 
CFR Code of Federal Regulations 
CLIA Clinical Laboratory Improvement Amendments 
CMP Clinical Monitoring Plan 
COC Certificate of  Confidentiality 
CONSORT Consolidated Standards of Reporting Trials 
CRF Case Report Form 
DCC Data Coordinating Center 
DHHS Department of Health and Human Services 
DSMB Data Safety Monitoring Board 
DRE Disease-Related Event 
EC Ethics Committee 
eCRF Electronic Case Report Forms 
FDA Food and Drug Administration 
FDAAA Food and Drug Administration Amendments Act of 2007 
FFR Federal Financial Report 
GCP Good Clinical Practice 
GLP Good Laboratory Practices 
GMP Good Manufacturing Practices 
GWAS Genome-Wide Association Studies 
HIPAA Health Insurance Portability and Accountability Act 
IB Investigatorâ€™s Brochure 
ICH International Conference on Harmonisation 
ICMJE International Committee of Medical Journal Editors 
IDE Investigational Device Exemption 
IND Investigational New Drug Application 
IRB Institutional Review Board 
ISM Independent Safety Monitor 
ISO International Organization for Standardization 
ITT Intention-To-Treat 
LSMEANS Least-squares Means 
MedDRA Medical Dictionary for Regulatory Activities 
MOP Manual of Procedures 
MSDS Material Safety Data Sheet 
NCT National Clinical Trial 
NIH National Institutes of Health 
NIH IC NIH Institute or Center 
OHRP Office for Human Research Protections 
PI Principal Investigator 
QA Quality Assurance 
QC Quality Control 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SMC Safety Monitoring Committee 
SOA Schedule of Activities 
SOC System Organ Class 
SOP Standard Operating Procedure 
UP Unanticipated Problem 
US United States 
37 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 12 REFERENCES 
1. Lerman JB, Joshi AA, Chaturvedi A, Abe rra TM, Dey AK, Rodante JA, Salahuddin T, 
Chung JH, Rana A, Teague HL, Wu JJ, Playfo rd MP, Lockshin BA, Chen MY, Sandfort V, 
Bluemke DA and Mehta NN. Coronary Plaque Ch aracterization in Psoria sis Reveals High-Risk 
Features That Improve Af ter Treatment in a Prosp ective Observational Study. Circulation . 
2017;136:263-276. 
2. Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, 
Harrington CL, Rivers JP, Chung JH , Kabbany MT, Natarajan B, Silv erman JI, Ng Q, Sanda GE, 
Sorokin AV, Baumer Y, Gerson E, Prussick RB,  Ehrlich A, Green LJ, Lockshin BN, Ahlman 
MA, Playford MP, Gelfand JM and Mehta NN. Asso ciation Between Skin and Aortic Vascular 
Inflammation in Patients With  Psoriasis: A Case-Cohort St udy Using Positron Emission 
Tomography/Computed Tomography. JAMA Cardiol . 2017;2:1013-1018. 
3. Leonardi CL, Powers JL, Matheson RT, Goffe  BS, Zitnik R, Wang A, Gottlieb AB and 
Etanercept Psoriasis Study G.  Etanercept as monotherapy in  patients with psoriasis. The New 
England journal of medicine . 2003;349:2014-22. 
4. Leonardi C, Matheson R, Zachariae C, Camer on G, Li L, Edson-Heredia E, Braun D and 
Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in  chronic plaque psoriasis. 
The New England journal of medicine . 2012;366:1190-9. 
5. Mease PJ. Inhibition of interleukin-17, inte rleukin-23 and the TH17 cell pathway in the 
treatment of psoriatic ar thritis and psoriasis. Curr Opin Rheumatol . 2015;27:127-33. 
6. Sterry W, Strober BE, Menter A and International Psoriasis C. Obesity in psoriasis: the 
metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and 
review. Br J Dermatol . 2007;157:649-55. 
7. Azfar RS and Gelfand JM. Psoriasis and metabolic disease: epidemiology and 
pathophysiology. Curr Opin Rheumatol . 2008;20:416-22. 
8. Armstrong AW, Harskamp CT and Armstrong EJ . The association between psoriasis and 
obesity: a systematic review and meta -analysis of observational studies. Nutr Diabetes . 2012;2:e54.  
9. Ricketts JR, Rothe MJ and Grant-Ke ls JM. Nutrition and psoriasis. Clin Dermatol . 
2010;28:615-26. 
10. Di Minno M N, Peluso R, Iervolino S, Russo lillo A, Lupoli R, Scarpa R and Ca RSG. 
Weight loss and achievement of minimal disease ac tivity in patients with psoriatic arthritis 
starting treatment with tumour ne crosis factor alpha blockers. Ann Rheum Dis . 2014;73:1157-62. 
11. Gisondi P, Del Giglio M, Di Francesco V,  Zamboni M and Girolomoni G. Weight loss 
improves the response of obese patie nts with moderate-to-severe chr onic plaque psoriasis to low- 
dose cyclosporine therapy: a ra ndomized, controlled, investigato r-blinded clinical trial. The 
American journal of clinical nutrition . 2008;88:1242-7. 
12. Diguet N, Trammell SAJ, Tannous C, Deloux R, Piquereau J, Mougenot N, Gouge A, 
Gressette M, Manoury B, Blanc J, Breton M, D ecaux JF, Lavery GG, Baczko I, Zoll J, Garnier 
A, Li Z, Brenner C and Mericskay M. Nicotin amide Riboside Preserves Cardiac Function in a 
Mouse Model of Dilated Cardiomyopathy. Circulation . 2018;137:2256-2273. 
13. Hou Y, Lautrup S, Cordonnier S, Wang Y, Cr oteau DL, Zavala E, Zhang Y, Moritoh K, 
O'Connell JF, Baptiste BA, Stevnsner TV, Matt son MP and Bohr VA. NAD(+) supplementation 
38 
Abbreviated Title: NR in psoriasis 
Version Date: 07/21/2023 
Template version date 07-29-2019  
 normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model 
with introduced DNA repair deficiency. Proceedings of the National Academy of Sciences of the 
United States of America . 2018;115:E1876-E1885. 
14. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, 
Chonchol M and Seals DR. Chronic nicotinamide riboside supplementation is  well-tolerated and 
elevates NAD(+) in healthy mid dle-aged and older adults. Nature communications . 2018;9:1286. 
15. Airhart SE, Shireman LM, Risler LJ, Anders on GD, Nagana Gowda GA,  Raftery D, Tian 
R, Shen DD and O'Brien KD. An open-label, non-randomized study of th e pharmacokinetics of 
the nutritional supplement nico tinamide riboside (NR) and its effects on blood NAD+ levels in 
healthy volunteers. PloS one . 2017;12:e0186459. 
16. Canto C, Houtkooper RH, Pirinen E, Youn DY,  Oosterveer MH, Ce n Y, Fernandez- 
Marcos PJ, Yamamoto H, Andr eux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, 
Sauve AA and Auwerx J. The NAD(+) precursor  nicotinamide riboside enhances oxidative 
metabolism and protects against high-fat diet-induced obesity. Cell metabolism . 2012;15:838-47. 
17. Benyo Z, Gille A, Kero J, Csiky M, Such ankova MC, Nusing RM, Moers A, Pfeffer K 
and Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. The 
Journal of clinical investigation . 2005;115:3634-40. 
18. Dollerup OL, Christensen B, Svart M, Sch midt MS, Sulek K, Ringgaard S, Stodkilde- 
Jorgensen H, Moller N, Brenner C, Treebak JT  and Jessen N. A randomi zed placebo-controlled 
clinical trial of nicotinamide riboside in obe se men: safety, insulin-sensitivity, and lipid- 
mobilizing effects. The American journal of clinical nutrition . 2018;108:343-353. 
19. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccuni ML, Fava 
D, Gragnoli C, Andreani D and et al. Double blind trial of nicotinamide in recent-onset IDDM (the 
IMDIAB III study). Diabetologia . 1995;38:848-52.  
20. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G and Kolb 
H. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS 
Group. Diabetes . 1998;47:980-4. 
21. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, 
Abel ED, Migaud ME and Brenner C. Nicotinamide riboside is uniquely and orally bioavailable 
in mice and humans. Nature communications . 2016;7:12948. 
22. Chi Y and Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 
with effects on energy meta bolism and neuroprotection. Current opinion in c linical nutrition and 
metabolic care . 2013;16:657-61. 